(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Shares in Rapid Micro Biosystems jumped Friday in premarket trading after it said it signed an agreement with Merck's life science business to distribute its microbiology testing platform. Shares ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...